Radio technology should be emphasized along with others
The academic and industrial fields should work together for development of Radio Technology (RT) on the occasion of the nation's hosting of the 9th Congress of the World Federation of Nuclear Medicine and Biology (WFNMB) scheduled for Oct. 22-27 in Seoul, Lee Kwan-haeng, CEO of Shinjin Medics said.
"It goes without saying that RT is the sector backing up the nation's future, along with Information Technology [IT], Bio Technology [BT] and Nano Technology [NT]," said Lee.
In an interview with Korea IT Times, Lee said that Shinjin Medics has been exerting itself for sustainable growth and development of RT as a research, development and production company in the RT field.
"I think the industrial-academic cooperation is the best way for persistent development of RT. Recently, study on IT, BT, NT and RT has been changing from an independent form in the past to a fusion-style pattern. In such fusion-style fields, it is difficult to make a success with sole efforts by industrial sector or academic sector. Through the WFNMB congress, the academic and industrial fields should work together for development of RT," he stressed.
On the Shinjin Medics' future nuclear power R&D projects in the bioscience field, Lee said that Shinjin Medics is an R&D company professionally producing diagnosis supplies and selling them to domestic and foreign markets.
"Diagnosis reagent is based on immunology and it applies an antigen-antibody reaction to diagnosis. However, as the process is very complicated and the degree of sensitiveness and interrelationship with other diseases and products should be considered, it is not so easy," said Lee. Accordingly, Shinjin Medics has been focused its R&D projects on the diagnosis materials sector, accumulating clinical know-how. Based on such knowledge, Shinjin Medics has developed world-class products and plans to increase the number of top products in the future.
Shinjin Medics also undertook nuclear power research and development projects from the government in April 1990 and since then it has succeeded in developing 32 kinds of RIA products, he said.
Through the nuclear power research and development project, Shinjin Medics has developed RIA products in various fields. In particular, it developed major products in the hepatitis field, the demands for which are growing rapidly in Asian regions, including South Korea.
As an initial stage, Shinjin Medics tried to follow the technology level of advanced countries about nuclear power-related diagnosis reagent. While passing through such processes, it has accumulated its own technology and finally developed some excellent products whose quality exceeds that of advanced countries, he said.
For instance, Shinjin Medics developed one-step product for the first time in the world in the Hbs Ag IRMA inspection that inspects hepatitis antigen. It also developed products measuring up to 1000 mIU in the Anti-HBs IRMA inspection that inspects hepatitis antibodies.
In the field of tumor blood inspection, the company has attained good results in the development of new technology that supplements demerits of the inspection that requires a long inspection period. Noting that nuclear power technology has a great merit in the diagnosis field, Lee said, "Among nuclear power technologies, Shinjin Medics uses isotope. The biggest merit of isotope in the diagnosis field is stability. It is a stable material that does not affected by external factors such as temperature and humidity and internal factors, including various chemical materials containing in the diagnosis reagent. Accordingly, the inspection result is very exact and reliable."
"However," he continued, "as I pointed out earlier, it also has a demerit requiring a long time for inspection. As a result, such demerit should be removed for development of nuclear medicine diagnosis inspection. I have confidence that the RIA field will develop further if we tide over such demerit, while making the bet use of its merits." On the company's core business project for 2006, Lee said that Shinjin Medics has been concentrating its efforts on shortening hours in the radioimmunoassay.
"If we succeed in this field, the radioimmunoassay will continue to develop, helping Shinjin Medics make great jump for outstanding development," he said.
The followings are excerpts from an interview with Lee Kwan-haeng, CEO of Shinjin Medics.
Q: Would you introduce your management philosophy and vision of your company
A: As CEO of a company specialized in RIA kits, I think that we should be sensitive to the changes and flow of diagnosis reagent and users' changing demands.
If we fail to effectively cope with the global changes of diagnosis reagent, the market's demands and competition with other inspection methods, we could not achieve development in the RIA field.
As a result, we are always making strenuous efforts to actively cope with changes and meet the needs of the times.
Q: Would you comment on the long-term business strategy of Shinjin Medics
A: On a long-term basis, we will continue study on new inspection methods in the new inspection field. For the development of new inspection ITEM, we will make a strong push for joint study of the industrial and academic fields.
By using our accumulated know-how on clinical tests of diagnosis reagent and relevant products, we will develop new and competitive products in the protein chip and DNA chip sectors, making our company one of the world's top companies in the diagnosis reagent field.
Q: Would you introduce the brief history of Shinjin Medics
A: Shinjin Medics was established in 1992 in order to import RIA and ELISA diagnostic products such as kits and instruments. Our activity as the distributor is structured into market segments and directed to various types of end customers, from large companies to small consumers, and from local medical centers to big hospitals.
Since its establishment in 1998, Shinjin Medics Laboratories has offered a wide range of products such as vitro RIA, ELISA and rapid immunodiagnostic kits, which fill the need of laboratory analysis, including hepatitis virus, tumor marker, thyroid function, infectious disease, fertility hormone and triple marker, etc.
Also, our laboratory has concentrated on developing techniques to produce recombinant antigen, monoclonal or polyclonal antibodies in the field of hepatitis and tumor marker, and we expect these paired bulk materials will be marketed in the near future.
Shinjin Medics, with its over 10 years' immunodiagnostic experience and talented masters and doctors in the laboratory, has consolidated its own position in vitro immunodiagnostic sectors both at home and abroad thanks to the research and development of new products, the highest quality and the making innovation.
We are also fulfilling research and development on RIA kits by the demand of the government. On the basis of important agreements as a new leader in this field, Shinjin Medics will be an important name as the producer and the developer in the field of immunology. |
저작권자 © Korea IT Times 무단전재 및 재배포 금지